


# ABSTRACT OF THE DISCLOSURE

This invention provides compounds defined by Formula I

5



I

or a pharmaceutically acceptable salt thereof,  
wherein R<sup>1</sup>, Q, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, and n are as defined in the specification. The invention  
also provides pharmaceutical compositions comprising a compound of Formula I,  
10 or a pharmaceutically acceptable salt thereof, as defined in the specification,  
together with a pharmaceutically acceptable carrier, diluent, or excipient. The  
invention also provides methods of inhibiting an MMP-13 enzyme in an animal,  
comprising administering to the animal a compound of Formula I, or a  
pharmaceutically acceptable salt thereof. The invention also provides methods of  
15 treating a disease mediated by an MMP-13 enzyme in a patient, comprising  
administering to the patient a compound of Formula I, or a pharmaceutically  
acceptable salt thereof, either alone or in a pharmaceutical composition. The  
invention also provides methods of treating diseases such as heart disease,  
multiple sclerosis, osteo- and rheumatoid arthritis, arthritis other than osteo- or  
20 rheumatoid arthritis, cardiac insufficiency, inflammatory bowel disease, heart  
failure, age-related macular degeneration, chronic obstructive pulmonary disease,  
asthma, periodontal diseases, psoriasis, atherosclerosis, and osteoporosis in a  
patient, comprising administering to the patient a compound of Formula I, or a  
pharmaceutically acceptable salt thereof, either alone or in a pharmaceutical  
25 composition. The invention also provides combinations, comprising a compound  
of Formula I, or a pharmaceutically acceptable salt thereof, together with another  
pharmaceutically active component as described in the specification.

30